PF-Atlas › Clinical Trials › NCT03551691

Proton Pump Inhibitors and Fat Absorption in Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Omeprazole 20mg Capsule · Phase 2

Registry ID
NCT03551691
Phase
Phase 2
Status
Completed
Drug / intervention
Omeprazole 20mg Capsule
Sponsor
Children's Hospital of Philadelphia
Start
2018-08-07
Enrollment
19
Locations
1

About this trial

This is a clinical trial with a cross over design investigating the effect of the proton pump inhibitor omeprazole on fat malabsorption in subjects with cystic fibrosis and pancreatic insufficiency. Participants will be randomized to receive either omeprazole or placebo for 28 days, then cross over and receive omeprazole or placebo for another 28 days. Markers of fat absorption will be measured after each treatment course.

View NCT03551691 on ClinicalTrials.gov →

Explore related

All Omeprazole 20mg Capsule trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03551691 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.